# OnCo record idera-pharmaceuticals (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/idera-pharmaceuticals/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "idera-pharmaceuticals" ;
  schema:name "Idera Pharmaceuticals"@en ;
  schema:alternateName "Idera Pharmaceuticals, Inc."@en, "Idera"@en, "Aceragen"@en ;
  schema:description "Idera was a Cambridge biotech whose injected TLR9 agonist tilsotolimod, given into tumours with ipilimumab, failed a phase 3 trial in anti-PD-1-refractory melanoma in 2021."@en ;
  schema:url <https://onco.cc/companies/idera-pharmaceuticals/>, <http://www.iderapharma.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <http://www.iderapharma.com>, <https://clinicaltrials.gov/search?lead=Idera%20Pharmaceuticals%2C%20Inc.>, <https://www.wikidata.org/wiki/Q30296240> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/melanoma/> ;
  onco:technologies <https://onco.cc/technologies/in-situ-vaccination/> ;
  onco:terms <https://onco.cc/terms/pivotal-trial/>, <https://onco.cc/terms/clinical-trial/> ;
  onco:trials <https://onco.cc/trials/nct03865082/> .